Could a simple pill replace painful shots for new moms at risk of clots?

NCT ID NCT07716332

Not yet recruiting Disease control Sponsor: Ron Beloosesky MD Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study compares two blood-thinning medicines given after delivery to prevent dangerous blood clots: apixaban (a pill taken twice a day) and enoxaparin (a daily shot). The trial enrolls women at high risk for clots after vaginal or cesarean birth. The main goal is to see which treatment is more convenient and easier for mothers to stick with, while also tracking safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apixaban (oral tablet) compared to enoxaparin (subcutaneous injection)
What this could lead to: If oral apixaban works as well as the injection, it could offer new mothers a simpler, less painful way to prevent dangerous blood clots after childbirth.
What could go wrong: This is a small study focused on convenience, not on proving apixaban prevents clots better. It may not detect rare safety issues like bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DVT PROPHYLAXIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

puerperal disorder venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DVT PROPHYLAXIS POSTPARTUM

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.